Literature DB >> 31092546

Characteristics and treatment strategies for severe tricuspid regurgitation.

Brenden S Ingraham1, Sorin V Pislaru1, Vuyisile T Nkomo1, Rick A Nishimura1, John M Stulak1, Joseph A Dearani1, Charanjit S Rihal1, Mackram F Eleid1.   

Abstract

OBJECTIVE: This study aimed to identify characteristics, spectrum of tricuspid regurgitation (TR) severity and treatment patterns in patients considered for intervention of severe TR at a tertiary centre. The population being considered for TR intervention is currently not well defined and the role of transcatheter interventions is unclear.
METHODS: The study involved 87 patients with severe TR considered for intervention from 1 March 2016 to 12 November 2018 at Mayo Clinic. Patients receiving medications alone were compared with those receiving intervention to identify patterns in demographics, clinical/echocardiographic associations and survival.
RESULTS: Mean age was 80±9 (56% female), 93% had atrial fibrillation and 64% had chronic kidney disease ≥3 a. Follow-up was 331±276 days; 95% were symptomatic with 6 min walk distance of 270±110 m. Loop diuretics were used in 93%; aldosterone antagonists in 35%. Mean tricuspid annular plane systolic excursion was 15.6±3.8 mm, effective regurgitant orifice area (EROA) 82±32 mm2 and stroke volume index 39±11 mL/m2; 48% had at least moderate right ventricular (RV) dysfunction, and 75% did not undergo intervention. Patients receiving intervention showed trends towards larger EROA (93±33 vs 75±31 mm2), better right ventricular function and more severe symptoms. Overall group 30-day and 1-year survival were 100% and 76%, respectively.
CONCLUSIONS: Patients with severe TR considered for intervention are commonly elderly with atrial fibrillation, advanced TR and RV dysfunction; 75% were treated with medications alone and not offered intervention. Patients with greater EROA, better RV function and more severe symptoms were more likely to receive intervention. These findings have implications for future trial design. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  TVR; device; minimally invasive; transcatheter intervention; tricuspid regurgitation

Mesh:

Substances:

Year:  2019        PMID: 31092546     DOI: 10.1136/heartjnl-2019-314741

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  5 in total

1.  Immediate, early and mid-term outcomes following balloon mitral valvotomy in patients having severe rheumatic mitral stenosis with significant tricuspid regurgitation.

Authors:  Krishna Kumar Mohanan Nair; Ajitkumar Valaparambil; Bijulal Sasidharan; Sanjay Ganapathi; Arun Gopalakrishnan; Narayanan Namboodiri; Harikrishnan Sivadasanpillai
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-07-27

2.  Early surgery can improve the outcomes of patients with severe tricuspid regurgitation undergoing tricuspid replacement.

Authors:  Kun Hua; Rui Zhao; Zhan Peng; Yunxiao Yang; Osmanaj Florian; Bin Mao; Xiubin Yang
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

3.  Determinants of Morbidity and Mortality Associated With Isolated Tricuspid Valve Surgery.

Authors:  Akram Kawsara; Fahad Alqahtani; Vuyisile T Nkomo; Mackram F Eleid; Sorin V Pislaru; Charanjit S Rihal; Rick A Nishimura; Hartzell V Schaff; Juan A Crestanello; Mohamad Alkhouli
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

4.  Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Shi Chen; Liang Chen; Ardan M Saguner; Kai Chen; Deniz Akdis; Alessio Gasperetti; Corinna Brunckhorst; Hanwei Tang; Guangran Guo; Man Rao; Xiangjie Li; Jiangping Song; Firat Duru; Shengshou Hu
Journal:  J Am Heart Assoc       Date:  2022-06-29       Impact factor: 6.106

5.  Progression of Chronic Kidney Disease and All-Cause Mortality in Patients with Tricuspid Regurgitation.

Authors:  Fabian Schipmann; Marwin Bannehr; Valentin Hähnel; Victoria Dworok; Jonathan Nübel; Christoph Edlinger; Michael Lichtenauer; Michael Haase; Michael Zänker; Christian Butter; Anja Haase-Fielitz
Journal:  Diseases       Date:  2022-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.